Advertisement

Adjuvant Intermittent Chemoimmunotherapy for Primary Breast Cancer: A Prospective Study with Immunologic Follow-Up

  • M. Betzler
  • W. Schreml
  • M. Lang
  • H. P. Lohrmann
  • H. D. Flad
  • P. Schlag
  • C. Herfarth
  • H. Heimpel
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 80)

Summary

In an interdisciplinary prospective study 50 patients surgically treated for breast cancer were treated with six monthly courses of aggressive adjuvant chemotherapy (adriamycin and cyclophosphamide) and were randomized to receive either immunotherapy with levamisole or no additional therapy. Probability of disease-free survival for the whole group is 54.9% at 42 months. There was no noticeable difference in disease-free survival for either pre- and postmenopausal women or for patients treated with or without levamisole. The addition of levamisole had no effect on the depression of in vitro immunologic functions during chemotherapy.

Keywords

Breast Cancer Primary Breast Cancer Hemorrhagic Cystitis Actuarial Method Large Primary Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Betzier M, Schlag P, Schreml W, Herfarth C (1978) Mammakarzinom: Stadieneinteilung, Therapie und Nachsorge. Med Klin 73:633Google Scholar
  2. 2.
    Betzier M, Flad HD, Schreml W, et al. (1979) Quantitative and functional studies of lymphocyte subpopulations during adjuvant chemo(immuno)therapy in patients with breast cancer. In: Flad HD, Herfarth Ch, Betzler M (eds) Immunodiagnosis and immunotherapy of malignant tumors. Springer, Berlin Heidelberg New YorkGoogle Scholar
  3. 3.
    Bonadonna G, Brusamolino E, Valagussa P, et al. (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405PubMedCrossRefGoogle Scholar
  4. 4.
    Bonadonna G, Valagussa P, Rossi A, et al. (1978) Are adjuvant trials altering the course of breast cancer? Semin Oncol 5:450–464PubMedGoogle Scholar
  5. 5.
    Fisher B, Carbone P, Economon SG, et al. (1975) l-Phenylalanine mustard (l-PAM) in the management of primary breast cancer: A report of early findings. N Engl J Med 292:117PubMedCrossRefGoogle Scholar
  6. 6.
    Flad HD, Betzier M, Schreml W, et al. (1978) Verhalten lymphatischer Subpopulationen unter zytostatischer Therapie. In: Huber H, Senn HJ, Falkensammer M (eds) Adjuvante zytostatische Chemotherapie. Zytostatische Therapie als Rezidivprophylaxe? Hämatologie und Bluttransfusion, vol 22. Springer, Berlin Heidelberg New York, S 25Google Scholar
  7. 7.
    Immich H (1977) Medizinische Statistik. Schattauer, StuttgartGoogle Scholar
  8. 8.
    Rojas AF, Mickiewicz E, Feierstein JN, Glait H, Olivari AJ (1976) Levamisole in advanced human breast cancer. Lancet 1:211PubMedCrossRefGoogle Scholar
  9. 9.
    Wendt AG, Jones SE, Salmon SE, et al. (1979) Adjuvant treatment of breast cancer with adriamycin-cyclophosphamide with or without radiation therapy. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer II. Grune & Stratton, New York, pp 63–70Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1982

Authors and Affiliations

  • M. Betzler
    • 1
  • W. Schreml
    • 1
  • M. Lang
    • 1
  • H. P. Lohrmann
    • 1
  • H. D. Flad
    • 1
  • P. Schlag
    • 1
  • C. Herfarth
    • 1
  • H. Heimpel
    • 1
  1. 1.Department für ChirurgieUniversität UlmGermany

Personalised recommendations